Top Page
iSpecimen
(NASDAQ:ISPC)
iSpecimen (ISPC) vs. SPDR S&P 500 ETF (SPY)
iSpecimen Business Overview & Revenue Model
iSpecimen Earnings Call Summary
iSpecimen Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.91M | 9.29M | 9.93M | 10.40M | 11.14M | 8.18M |
| Gross Profit | 1.93M | 3.99M | 5.11M | 5.65M | 5.89M | 4.60M |
| EBITDA | -8.00M | -12.73M | -9.10M | -8.80M | -5.86M | -1.74M |
| Net Income | -10.19M | -12.50M | -11.10M | -9.04M | -10.02M | -6.76M |
Balance Sheet | ||||||
| Total Assets | 6.03M | 9.35M | 15.82M | 24.62M | 35.72M | 6.21M |
| Cash, Cash Equivalents and Short-Term Investments | 588.77K | 1.88M | 5.01M | 15.31M | 27.74M | 695.91K |
| Total Debt | 287.88K | 312.17K | 196.24K | 185.85K | 3.42M | 12.77M |
| Total Liabilities | 5.41M | 6.04M | 6.08M | 4.31M | 5.93M | 33.49M |
| Stockholders Equity | 621.97K | 3.31M | 9.74M | 20.31M | 29.79M | -27.28M |
Cash Flow | ||||||
| Free Cash Flow | -6.19M | -8.30M | -10.55M | -9.01M | -11.71M | -1.39M |
| Operating Cash Flow | -5.94M | -8.26M | -5.81M | -5.82M | -10.67M | -288.38K |
| Investing Cash Flow | -253.47K | 1.98M | -7.23M | -3.19M | -1.04M | -1.10M |
| Financing Cash Flow | 4.63M | 5.82M | 70.89K | -3.42M | 38.75M | 2.03M |
iSpecimen Technical Analysis
iSpecimen Risk Analysis
iSpecimen Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | 18.54M | -1.10 | 510.89% | ― | 4.10% | 67.32% | |
44 Neutral | $11.70M | ― | -303.74% | ― | -43.77% | 55.78% | |
42 Neutral | 3.84M | >-0.01 | ― | ― | -2.96% | 89.71% | |
34 Underperform | 3.62M | -0.01 | ― | ― | ― | 77.66% | |
26 Underperform | 12.58M | ― | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
iSpecimen Corporate Events
On September 4, 2025, iSpecimen Inc. announced an update on its strategic initiative to integrate digital assets into its business model by building a $200 million corporate treasury reserve based on the Solana blockchain ecosystem. Since its initial announcement in August 2025, the company has been approached by several cryptocurrency-related companies offering opportunities in tokenized real-world assets and highly ranked cryptocurrencies. iSpecimen plans to establish a SOL-based treasury program to diversify its balance sheet and support long-term growth, with a focus on a buy and HODL strategy and purchasing locked SOL at a discount. This initiative is expected to enhance shareholder value and allow for liquidity management through partial diversification and spot trading.
The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On August 21, 2025, iSpecimen Inc. announced the successful completion of Milestone 1 in its digital transformation program, which involved the installation of the Salestack platform and the provisioning of modern infrastructure. This milestone enhances the iSpecimen Marketplace® with a cloud-native architecture, improving reliability, security, and innovation capabilities, and sets the stage for the next phase of integration aimed at achieving end-to-end operational efficiency.
The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On August 7, 2025, iSpecimen Inc. announced a strategic initiative to integrate digital assets into its business model by establishing a corporate treasury reserve of up to $200 million based on the Solana blockchain ecosystem. This move, supported by WestPark Capital and BlockArrow, aims to enhance iSpecimen’s technological leadership in the life sciences by leveraging Solana’s high throughput, low transaction costs, and robust security features, potentially positioning the company as a leader in digital asset adoption and innovation.
On July 31, 2025, iSpecimen Inc. entered into a Securities Purchase Agreement with accredited investors, resulting in a private placement of 1,559,828 shares of common stock or pre-funded warrants, generating gross proceeds of approximately $1.75 million. The placement, which closed on August 4, 2025, was conducted in compliance with Nasdaq rules and involved WestPark Capital, Inc. as the exclusive placement agent. The company plans to allocate $500,000 of the net proceeds for marketing and advertising services, with the remainder used for working capital and general corporate purposes. Additionally, iSpecimen entered into a registration rights agreement to facilitate the resale of shares and a marketing agreement with IR Agency LLC to enhance its visibility in the financial community.
On July 23, 2025, iSpecimen Inc. entered into an underwriting agreement with WestPark Capital, Inc. to sell 5,714,283 securities in an underwritten public offering, closing on July 25, 2025. The offering raised approximately $4 million in gross proceeds, with net proceeds of around $3.53 million, which the company plans to use for marketing, a software purchase, and general corporate purposes. The offering enhances iSpecimen’s financial resources, potentially strengthening its market position and operational capabilities.
On June 18, 2025, Richard J. Paolone and John L. Brooks III resigned from the Board of Directors of iSpecimen Inc., with no disagreements cited regarding company operations or policies. Subsequently, on June 20, 2025, Anthony Lau was appointed to the Board, bringing extensive experience in corporate governance and financial oversight, which is expected to enhance the company’s governance and oversight capabilities.